Evidence map›Paper›PMID 31827897›Full record

ArticleFuture science OA2019

Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN

Chaitanya Kumar, Jasmine Bagga, Srikanth Chiliveru, Sakshi Kohli, Asmi Bharadwaj, Minish Jain, Shriram Inamdar, Bandana Sharan

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chaitanya KumarR&D, APAC Biotech Pvt Ltd, Gurgaon, India.
Jasmine BaggaR&D, APAC Biotech Pvt Ltd, Gurgaon, India.
Srikanth ChiliveruR&D, APAC Biotech Pvt Ltd, Gurgaon, India.
Sakshi KohliR&D, APAC Biotech Pvt Ltd, Gurgaon, India.
Asmi BharadwajR&D, APAC Biotech Pvt Ltd, Gurgaon, India.
Minish JainMedical Oncology, Ruby Hall Clinic, Pune, India.
Shriram InamdarXylem Clinical Research Pvt Ltd, Pune, India.
Bandana SharanR&D, APAC Biotech Pvt Ltd, Gurgaon, India.
Biotech Park · INRuby Hall Clinic · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN

Indexed as

APCEDEN®dendritic cellsIFN-γimmunotherapyneutrophil lymphocyte ratioplatelet lymphocyte ratioprostate adenocarcinomaregulatory T cells

Identifiers

PMID31827897
PMCPMC6900976
OpenAlexW2982633597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.